Fuzheng Jiedu granules against disease progression among high-risk adults with non-severe COVID-19: a multicenter retrospective cohort study
BackgroundFuzheng Jiedu (FZJD) granules are widely used to treat coronavirus disease (COVID-19) since their market approval, but their clinical effectiveness remains uncertain. In this study, we aimed to evaluate the effectiveness of FZJD in reducing disease progression in high-risk adults with COVI...
Saved in:
| Main Authors: | Qiaoli Hua, Danwen Zheng, Jingwei Shui, Tong Zhang, Shengle Qin, Hanhong Zhang, Bo Yu, Longde Wang, Hailang He, Xinghua Tan, Qiumin Chen, Yang Yang, Weng Heng, Yihang Cai, Xiaohua Xu, Qing Liu, Yuntao Liu, Rongyuan Yang, Zhongde Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1523004/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FoxO1 as a Hub in Immunosenescence Induced by Hepatocellular Carcinoma and the Effect of Yangyin Fuzheng Jiedu Prescription
by: Xie Y, et al.
Published: (2025-03-01) -
Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma
by: Yuqing Xie, et al.
Published: (2023-02-01) -
Warning indicators of COVID-19 severity: a retrospective observational study integrating modern biomarkers and traditional tongue features
by: Zhang Jing, et al.
Published: (2025-04-01) -
Persistence of SARS-CoV-2-IgG antibody durability in convalescent COVID-19 patients 6 months after the natural infection
by: Qiaoli Hua, et al.
Published: (2025-08-01) -
Huanglian Jiedu Decoction improves the"central-peripheral"inflammatory microenvironment and enhances the cognitive function of APP/PS1 mice by inhibiting the activation of NLRP3 inflammasome mediated by gut microbiota
by: Yani Zhang, et al.
Published: (2025-08-01)